Skip to content

Human Sodium Balance Study

Sodium Regulation in Individuals on Known Dietary Sodium Intake

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04110262
Acronym
MEASURE
Enrollment
52
Registered
2019-10-01
Start date
2021-11-10
Completion date
2024-08-12
Last updated
2024-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Blood pressure, Sodium, Salt, Randomized controlled trial, balance, humans

Brief summary

The overall objective of this study is to examine how dietary sodium is used by the body. In a racially diverse sample of adults, the investigators will examine the effects of high and low dietary sodium intake on the storage and excretion of sodium and determine whether sodium distribution affects blood pressure. This has implications for how investigators interpret studies that use urine biomarkers of sodium. Study findings about tissue sodium storage also have implications for managing hypertension and related conditions.

Interventions

OTHERHigh dietary sodium intake

Fourteen day feeding period of high dietary sodium (3400 mg/day)

OTHERLow dietary sodium intake

Fourteen day feeding period of low dietary sodium (2300 mg/day)

Sponsors

University of California, San Diego
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)

Masking description

Throughout data collection, study data collectors and the study coordinator will remain blinded to participants' exposure group.

Intervention model description

Dietary intervention consisting of two 25-day feeding periods separated by a 10-day washout.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years old; * Diagnosed with high blood pressure or pre-hypertension (systolic blood pressure (SBP) \> 120 mm Hg or diastolic blood pressure (DBP) \> 80 mm Hg); * Taking no more than two medications for high blood pressure; * Currently has a primary care provider; * Willing to eat all meals provided by the study for two 14-day feeding periods; * Willing to complete study measurement procedures.

Exclusion criteria

* Diabetes; * Smoker; * Serious food allergies; * Currently pregnant or planning to become pregnant

Design outcomes

Primary

MeasureTime frameDescription
Estimated sodium concentration in skin and muscle60 daysThe concentration of sodium in skin and muscle will be measured, and the difference in concentrations resulting from high versus low sodium intakes will be calculated. Skin and muscle sodium stores will be non-invasively quantified using 23sodium-magnetic resonance imaging (23Na-MRI).
Estimated sodium concentration in bone60 daysThe concentration of sodium in bone will be measured, and the difference in concentrations resulting from high versus low sodium intakes will be calculated. Sodium storage in bone will be measured non-invasively using in vivo neutron activation analysis (IVNAA) technology to quantify the concentration of Na in the hand.
Concentration of sodium, potassium, and hormone regulators in excreted urine60 daysUrinary concentration of sodium, potassium, and hormones (renin, angiotensin, aldosterone, free cortisol, free cortisone, glucocorticoid, and mineralocorticoid) will be measured and variation over time will be calculated.
Blood pressure60 daysBlood pressure under high versus low dietary sodium conditions will be measured.

Secondary

MeasureTime frameDescription
Racial differences in concentrations of sodium in skin, muscle and bone60 daysBlacks/African Americans mean sodium concentrations versus the average of the means of each of the other racial/ethnic groups will be examined.
Racial differences in concentration of urinary potassium excretion60 daysThe concentration of potassium excreted in urine will be compared between Blacks/African Americans versus the pooled sample of other racial/ethnic groups.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026